Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BARTLEY JOSEPH GILL

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1346669066
CMS profile
600789
Location
SUGAR LAND, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$65,458.42

275 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 6 of 6; records 251–275 of 275 matching records. This page contains 25 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BARTLEY JOSEPH GILL

NPI 1346669066 · CMS profile ID 600789

Allopathic & Osteopathic Physicians / Internal Medicine

SUGAR LAND, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 6 of 6; records 251–275 of 275 matching records. This page contains 25 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1346669066?year=2019&recipient=provider&page=6#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BARTLEY JOSEPH GILL, NPI 1346669066, CMS profile ID 600789. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–275 of 275 matching records. This page contains 25 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346669066?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). BARTLEY JOSEPH GILL, NPI 1346669066, CMS profile ID 600789. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–275 of 275 matching records. This page contains 25 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346669066?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
BARTLEY JOSEPH GILL, NPI 1346669066, CMS profile ID 600789, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 6; records 251–275 of 275 matching records. This page contains 25 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1346669066?year=2019&recipient=provider&page=6#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

275 matching records · $65,458.42 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 275 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 251–275 of 275.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Almirall LLC $13.6002/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676655705 CMS
Lilly USA, LLC $116.2402/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657686919 CMS
Lilly USA, LLC $4,050.0002/19/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657676457 CMS
Celgene Corporation $14.7202/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672743213 CMS
AbbVie, Inc. $16.1602/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647819851 CMS
Novartis Pharmaceuticals Corporation $0.7702/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659563555 CMS
Lilly USA, LLC $253.4902/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657686917 CMS
Lilly USA, LLC $31.5002/09/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657697273 CMS
Lilly USA, LLC $331.2002/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657700741 CMS
AbbVie, Inc. $16.3502/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647819853 CMS
Novartis Pharmaceuticals Corporation $16.2102/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659563553 CMS
Lilly USA, LLC $307.9602/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657686913 CMS
Lilly USA, LLC $21.8502/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657697275 CMS
Novartis Pharmaceuticals Corporation $2.3002/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659563551 CMS
Celgene Corporation $21.3401/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672723749 CMS
Sun Pharmaceutical Industries Inc. $21.9701/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704597885 CMS
AbbVie, Inc. $124.9901/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647819845 CMS
Regeneron Healthcare Solutions, Inc. $18.2301/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673383485 CMS
AbbVie, Inc. $17.7901/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647819847 CMS
AbbVie, Inc. $23.9401/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647819849 CMS
Novartis Pharmaceuticals Corporation $24.5801/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659563547 CMS
Novartis Pharmaceuticals Corporation $16.8501/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659563525 CMS
Galderma Laboratories, L.P. $1.7901/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687681781 CMS
Lilly USA, LLC $22.0801/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657693825 CMS
Novartis Pharmaceuticals Corporation $2.3101/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659563541 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $65,458.42 275
PY2020 $7,516.85 66
PY2021 $17,995.33 138
PY2022 $31,575.80 188
PY2023 $27,963.03 196
PY2024 $19,905.76 171
PY2025 $47,679.06 211

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $307,091.06 39
PY2024 Recipient $1,588.18 10
PY2024 Principal investigator $287,170.67 32
PY2023 Recipient $8,828.02 2
PY2023 Principal investigator $87,260.72 6
PY2022 Recipient $125.00 2
PY2022 Principal investigator $14,027.00 2
PY2021 Recipient $8,351.55 2
PY2021 Principal investigator $29,273.40 1
PY2020 Recipient $200.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

39 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $12,000.00 12/31/2025 Non-covered Recipient Entity
Complete Dermatology PLLC
A PHASE 2B RANDOMIZED DOUBLEBLIND 12WEEK PLACEBOCONTROLLED STUDY WITH A 12WEEK DOUBLEBLIND EXTENSION PERIOD TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB PF06651600 IN ADULT PARTICIPANTS WITH CHRONIC SPONTANEOUS URTICARIA No dispute reported 06/30/2026 1228737986
Principal investigator 1 SANOFI US SERVICES INC. $288.77 12/22/2025 Non-covered Recipient Entity
Complete Dermatology Pllc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156687
Principal investigator 1 SANOFI US SERVICES INC. $9,023.00 12/22/2025 Non-covered Recipient Entity
Complete Dermatology Pllc
Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) No dispute reported 06/30/2026 1226156697
Principal investigator 1 SANOFI US SERVICES INC. $15,847.00 12/22/2025 Non-covered Recipient Entity
Complete Dermatology Pllc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156708
Principal investigator 1 PFIZER INC. $1,605.66 11/26/2025 Non-covered Recipient Entity
Complete Dermatology
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228739038
Principal investigator 1 PFIZER INC. $3,690.96 11/04/2025 Non-covered Recipient Entity
Complete Dermatology
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228737668
Principal investigator 1 SANOFI US SERVICES INC. $15,143.00 11/04/2025 Non-covered Recipient Entity
Complete Dermatology Pllc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156632
Principal investigator 1 SANOFI US SERVICES INC. $12,907.90 10/14/2025 Non-covered Recipient Entity
Complete Dermatology Pllc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226156572
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,541.06 10/08/2025 Non-covered Recipient Entity
COMPLETE DERMATOLOGY, INC
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately co No dispute reported 06/30/2026 1190304977
Principal investigator 1 SANOFI US SERVICES INC. $2,100.00 10/06/2025 Non-covered Recipient Entity
Complete Dermatology Pllc
Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) No dispute reported 06/30/2026 1226156564
Principal investigator 1 SANOFI US SERVICES INC. $1,960.00 10/06/2025 Non-covered Recipient Entity
Complete Dermatology Pllc
Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) No dispute reported 06/30/2026 1226156568
Principal investigator 1 SANOFI US SERVICES INC. $3,323.00 09/29/2025 Non-covered Recipient Entity
Complete Dermatology Pllc
Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) No dispute reported 06/30/2026 1226156552
Principal investigator 1 SANOFI US SERVICES INC. $4,585.00 09/29/2025 Non-covered Recipient Entity
Complete Dermatology Pllc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156560
Principal investigator 1 SANOFI US SERVICES INC. $11,142.00 09/15/2025 Non-covered Recipient Entity
Complete Dermatology Pllc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156548
Principal investigator 1 PFIZER INC. $1,500.00 09/03/2025 Non-covered Recipient Entity
Complete Dermatology
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228760151
Principal investigator 1 SANOFI US SERVICES INC. $27,014.00 08/18/2025 Non-covered Recipient Entity
Complete Dermatology Pllc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156536
Principal investigator 1 SANOFI US SERVICES INC. $3,408.00 08/11/2025 Non-covered Recipient Entity
Complete Dermatology Pllc
Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) No dispute reported 06/30/2026 1226156532
Principal investigator 1 SANOFI US SERVICES INC. $5,976.00 08/04/2025 Non-covered Recipient Entity
Complete Dermatology Pllc
Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) No dispute reported 06/30/2026 1226156508
Principal investigator 1 SANOFI US SERVICES INC. $17,270.00 07/14/2025 Non-covered Recipient Entity
Complete Dermatology Pllc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156478
Principal investigator 1 SANOFI US SERVICES INC. $14,564.00 07/14/2025 Non-covered Recipient Entity
Complete Dermatology Pllc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226156481
Principal investigator 1 SANOFI US SERVICES INC. $4,668.00 07/02/2025 Non-covered Recipient Entity
Complete Dermatology Pllc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226156485
Principal investigator 1 SANOFI US SERVICES INC. $3,322.00 06/16/2025 Non-covered Recipient Entity
Complete Dermatology Pllc
Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) No dispute reported 06/30/2026 1226156437
Principal investigator 1 SANOFI US SERVICES INC. $17,600.00 06/16/2025 Non-covered Recipient Entity
Complete Dermatology Pllc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156449
Principal investigator 1 PFIZER INC. $2,695.00 05/30/2025 Non-covered Recipient Entity
Complete Dermatology
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228772760
Principal investigator 1 SANOFI US SERVICES INC. $4,668.00 05/27/2025 Non-covered Recipient Entity
Complete Dermatology Pllc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226156431
Principal investigator 1 SANOFI US SERVICES INC. $3,666.00 05/19/2025 Non-covered Recipient Entity
Complete Dermatology Pllc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156466
Principal investigator 1 SANOFI US SERVICES INC. $6,226.00 04/14/2025 Non-covered Recipient Entity
Complete Dermatology Pllc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156407
Principal investigator 1 SANOFI US SERVICES INC. $11,654.60 04/14/2025 Non-covered Recipient Entity
Complete Dermatology Pllc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226156421
Principal investigator 1 PFIZER INC. $1,632.36 04/08/2025 Non-covered Recipient Entity
Complete Dermatology
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228781108
Principal investigator 1 SANOFI US SERVICES INC. $15,858.00 03/24/2025 Non-covered Recipient Entity
Complete Dermatology Pllc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156383
Principal investigator 1 SANOFI US SERVICES INC. $4,224.60 03/24/2025 Non-covered Recipient Entity
Complete Dermatology Pllc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226156389
Principal investigator 1 SANOFI US SERVICES INC. $12,221.00 02/24/2025 Non-covered Recipient Entity
Complete Dermatology Pllc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226156387
Principal investigator 1 Eli Lilly and Company $9,448.50 02/05/2025 Non-covered Recipient Entity
COMPLETE DERMATOLOGY
AN OPEN-LABEL, 24-WEEK STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS AND SKIN OF COLOR No dispute reported 06/30/2026 1187878169
Principal investigator 1 Eli Lilly and Company $13,207.90 02/05/2025 Non-covered Recipient Entity
COMPLETE DERMATOLOGY
AN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB No dispute reported 06/30/2026 1187880347
Principal investigator 1 PFIZER INC. $1,159.56 02/05/2025 Non-covered Recipient Entity
Complete Dermatology
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228769159
Principal investigator 1 SANOFI US SERVICES INC. $3,393.00 02/04/2025 Non-covered Recipient Entity
Complete Dermatology Pllc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226156362
Principal investigator 1 SANOFI US SERVICES INC. $8,756.00 02/04/2025 Non-covered Recipient Entity
Complete Dermatology Pllc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156372
Principal investigator 1 Eli Lilly and Company $45.19 01/27/2025 Non-covered Recipient Entity
COMPLETE DERMATOLOGY
AN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB No dispute reported 06/30/2026 1187880349
Principal investigator 1 SANOFI US SERVICES INC. $8,756.00 01/21/2025 Non-covered Recipient Entity
Complete Dermatology Pllc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156375